SPINRAZA (nusinersen) is a drug developed by Biogen and approved by the FDA to treat Spinal Muscular Atrophy (https://www.spinraza.com for more information). In Japan, it was only available for SMA type 1 until July 2017. Now, it is available for all types.
Takami will start his treatment and receive his first injection in March 2018. The cost is partially (greatly) covered by the Japanese NHI, however, it will be a real struggle to afford the rest.
Every amount will help reduce this cost to a minimum.
I truly believe that Takami will run one day, and we would like to invite you to run with us someday.